Teladoc Health (NYSE:TDOC) CEO Charles Divita III Sells 17,805 Shares of Stock

Teladoc Health, Inc. (NYSE:TDOC) CEO Charles III sold 17,805 shares of the business’s stock in a transaction dated Friday, September 11th. The shares were sold at an average price of $6.10, for a total value of $108,610.50. Following the sale, the chief executive officer owned 465,535 shares of the company’s stock, valued at approximately $2,839,763.50. This represents a 3.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Teladoc Health Stock Up 5.6%

Shares of NYSE:TDOC opened at $6.51 on Tuesday. The stock has a market capitalization of $1.18 billion, a PE ratio of -6.57 and a beta of 2.12. The firm’s 50 day moving average price is $7.46 and its 200-day moving average price is $6.78. Teladoc Health, Inc. has a twelve month low of $4.40 and a twelve month high of $9.89.

Teladoc Health (NYSE:TDOC) last announced its earnings results on Wednesday, July 29th. The health services provider reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.04. Teladoc Health had a negative net margin of 7.13% and a negative return on equity of 12.15%. The company had revenue of $606.93 million during the quarter, compared to analyst estimates of $615.44 million. During the same period in the previous year, the business posted ($0.19) earnings per share. The firm’s quarterly revenue was down 4.0% compared to the same quarter last year. Teladoc Health has set its Q3 2026 guidance at -0.300–0.200 EPS and its FY 2026 guidance at -1.000–0.750 EPS. Analysts expect that Teladoc Health, Inc. will post -0.9 earnings per share for the current fiscal year.

Institutional Trading of Teladoc Health

Large investors have recently added to or reduced their stakes in the company. Versant Capital Management Inc increased its holdings in shares of Teladoc Health by 33.3% in the 2nd quarter. Versant Capital Management Inc now owns 8,207 shares of the health services provider’s stock worth $70,000 after buying an additional 2,052 shares during the last quarter. ProShare Advisors LLC lifted its holdings in shares of Teladoc Health by 8.2% in the 4th quarter. ProShare Advisors LLC now owns 32,532 shares of the health services provider’s stock valued at $228,000 after acquiring an additional 2,457 shares during the last quarter. HighTower Advisors LLC lifted its holdings in shares of Teladoc Health by 20.8% in the 2nd quarter. HighTower Advisors LLC now owns 16,808 shares of the health services provider’s stock valued at $143,000 after acquiring an additional 2,893 shares during the last quarter. Allworth Financial LP bought a new stake in Teladoc Health during the second quarter worth approximately $25,000. Finally, Twin Lakes Capital Management LLC bought a new stake in Teladoc Health during the second quarter worth approximately $26,000. Institutional investors own 76.82% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have weighed in on TDOC. Weiss Ratings reiterated a “sell (d-)” rating on shares of Teladoc Health in a research report on Wednesday, August 19th. Bank of America boosted their target price on shares of Teladoc Health from $9.00 to $10.50 and gave the stock a “buy” rating in a report on Tuesday, July 7th. Citigroup cut their target price on shares of Teladoc Health from $11.00 to $7.50 and set a “neutral” rating for the company in a research note on Monday, August 3rd. Finally, Canaccord Genuity Group reduced their price target on shares of Teladoc Health from $11.00 to $10.00 and set a “buy” rating on the stock in a report on Thursday, July 30th. Five equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $7.54.

About Teladoc Health

Teladoc Health, Inc is a virtual healthcare company that provides telehealth services and technology to individuals, employers, health plans, health systems and other organizations. Its platform enables patients to connect with healthcare professionals remotely through phone, video and digital tools, supporting access to medical care across a range of specialties.

The company’s offerings include general medical consultations, mental health services through BetterHelp, expert medical opinions, chronic condition management and digital health programs.